Company name
Diatheva S.R.L.
Company profile
Diatheva develops therapeutic antibodies for oncology and infectious diseases. DIA12.3 is a fully human IgG1 mAb targeting the CEACAM1 immune checkpoint. Currently in preclinical development it is designed to overcome resistance to ICIs therapies in solid tumors including NSCLC, bladder and pancreatic cancers by restoring NK and T-cell cytotoxicity. Our pipeline includes additional mAbs for leukemia and resistant fungal infections. We seek strategic partners for Phase 1 entry
Date, time and room information
Tuesday, May 5, 14:15 - 14:30, room Montreal
Category
Clinical stage development company
Speaker information
| Name | Position | Institution |
|---|---|---|
| Valentina Fiori | Biologics R&D Manager |
